Did you know? I-Corps at NIH is a hands-on entrepreneurship training program designed for Phase I companies that received SBIR or STTR funding from NIH or the CDC.
During eight weeks, you’ll learn how to focus your business plan and where to find the tools you need to help commercialize your product. And there’s no cost to you – a $55,000 supplement covers program costs!
-
Receive training from biotech sector experts
-
Hone your target market by engaging with potential customers
-
Expand your professional network
-
Build the confidence and skills to create a comprehensive business model
This cohort begins in March 2024. The sessions will be held virtually except for the in-person kickoff in Houston, TX, and the in-person closeout session in Bethesda, MD.
Applications for the next cohort are due on Wednesday, November 15, 2023, at 5:00 p.m., your local time.
The National Institute on Drug Abuse (NIDA) is looking for teams of participants to submit their research ideas that may be developed into successful new products and startups that address many different aspects of substance use disorder (SUD), including social determinants of health (SDOH).
The potential startup founders must have the passion, drive, discipline, and ability to work collaboratively and have an eagerness to be coached by NIDA biomedical entrepreneurship experts. The teams must also have a research idea directly related to SUD or that could be extended or adapted to be useful for SUD. In Stage 1, up to 12 teams will be selected to receive a 6-month mentorship from NIDA biomedical entrepreneurial experts and may receive cash prizes of up to $10,000 per team in Stage 2.
NIDA expects that the new ideas and startups will contribute to the pool of innovative small business companies that can successfully compete for NIDA’s small business grants.
Contact: Sara Lioi (NIDAChallenge@nih.gov).
Submissions due on Wednesday, November 15, 2023, at 6:00 p.m. ET.
The Rapid Acceleration of Diagnostics Technology (RADx® Tech) Fetal Monitoring Challenge will award up to $2 million in prizes to accelerate the development of diagnostic and monitoring technologies to reduce the risk of fetal morbidity and mortality and thus improve fetal and neonatal health outcomes. The application deadline is Friday, November 17, 2023.
NIDA recently released a new funding opportunity that is soliciting proposals for the development of technologies to address health-related social needs that impact substance use disorders (SUD) that focus on reducing costs, time, and increasing access. Areas of interest in addressing health-related social needs include but are not limited to housing instability, non-medical transportation, food insecurity, utility needs and personal safety. The products should provide the best feasible and accessible opportunities for the intended end-users to measurably improve their health-related social needs and SUD.
You can find more information about the Seeking Products to Address Social Needs impacting Substance Use Disorders (SUD) funding opportunities here: RFA-DA-25-048 (SBIR); RFA-DA-25-047 (STTR).
You may also contact NIDASBIR@nih.gov if you are interested in a technical assistance meeting with a program officer.
Application Deadline: Wednesday, March 13, 2024.
When the SBIR, STTR, and related pilot programs were reauthorized for FY2023-2025, the SBIR and STTR Extension Act of 2022 made several changes to the SBIR and STTR programs. Policy changes were announced June 12 through this Notice: Implementation of the NIH SBIR and STTR Foreign Disclosure Pre-award and Post-Award Requirements (NOT-OD-23-139).
Key elements include:
- disclosure requirements regarding ties to foreign countries,
- a requirement for federal agencies that manage SBIR and STTR programs to establish a due diligence program to assess security risks posed by applicants, and
- denial of award and recovery authority provisions when ties to foreign countries of concern pose a significant risk.
This policy applies to all NIH, CDC, FDA, and ACL competing applications for SBIR or STTR funding on or after September 5, 2023. More information and resources will be provided in the near future.
|
